Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Upper Gastrointestinal Bleeding Due to a Peptic Ulcer
TL;DR: Patients with bleeding ulcers due to NSAIDs other than low-dose aspirin should discontinue NSAIDs; if NSAIDs must be resumed, a cyclooxygenase-2 (COX-2)–selective NSAID plus a proton-pump inhibitor should be resumed.
Journal ArticleDOI
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Nalinie Joharatnam-Hogan,Fay H. Cafferty,Richard A Hubner,Daniel Swinson,Sharmila Sothi,Kamalnayan Gupta,Stephen Falk,Kinnari Patel,Nicola Warner,Victoria Kunene,Sam Rowley,Komel Khabra,Timothy J. Underwood,Janusz Jankowski,John Bridgewater,Anne Crossley,Verity Henson,L. Berkman,Duncan C. Gilbert,Howard Kynaston,Alistair Ring,David Cameron,Farhat V N Din,Janet Graham,Timothy Iveson,Richard Adams,Anne L. Thomas,Richard H. Wilson,C.S. Pramesh,Ruth E. Langley,John Burn,Sue Campbell,Lisa Capaldi,Yvonne Carse,Durga Gadgil,Arnold Goldman,Sudeep Gupta,Gregory Leonard,Mairead MacKenzie,Mahesh K. B. Parmar,Carlo Patrono,Russell D. Petty,Peter M. Rothwell,Robert Steele +43 more
TL;DR: Toxicity has been low and there is no evidence of a difference in adherence, acceptance of randomisation, or toxicity between the different cancer cohorts, and trial recruitment continues to determine whether aspirin could offer a potential low cost and well tolerated therapy to improve cancer outcomes.
Journal ArticleDOI
The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk
TL;DR: Upper GI symptoms can lead to nonadherence to, and discontinuation of, low-dose ASA CV-protective therapy, which is a mainstay of cardiovascular protection in patients at high risk of CV events.
Journal ArticleDOI
Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions.
TL;DR: In primary prevention, the appropriate and judicious use of aspirin by clinicians based on individual clinical judgments that weigh their absolute benefits against the absolute risks of the drug, will avoid premature morbidity and possibly, mortality.
Journal ArticleDOI
Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.
Ae Jin Kim,Hye Jin Lim,Han Ro,Kwang Pil Ko,Song Yi Han,Jae Hyun Chang,Hyun Hee Lee,Wookyung Chung,Ji Yong Jung +8 more
TL;DR: The results suggest that the use of low-dose aspirin in patients with CKD may have harmful consequences related to the development of CVD and renal progression.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.